Inmode Ltd Intrinsic Value Calculator – INMODE LTD Reports FY2023 Q2 Earnings Results for Period Ending June 30, 2023.
August 3, 2023
🌥️Earnings Overview
INMODE LTD ($NASDAQ:INMD) revealed its FY2023 Q2 financial results on July 27 2023 for the period ending June 30 2023. The total revenue for the quarter was an impressive USD 136.1 million, representing a 19.8% increase from the preceding year. Net income also experienced a significant rise with a 26.5% year over year increase to USD 55.7 million.
Price History
The company’s stock opened at $46.1, but closed at $44.1, down by 2.2% from its previous closing price of $45.0. This was the second consecutive quarter of decline in the stock’s price, indicating that investors have not been impressed with the company’s performance in recent times. Analysts had expected the company to make some improvements and report better results compared to the previous quarter, however it appears that the stock market has not been quite satisfied with the results. INMODE LTD‘s growth rate has been slowing down, as the company has failed to reach the market expectations for the past few quarters.
This is a worrying sign for investors, as it may indicate that the company is not able to sustain its position as one of the top players in its industry. If the trend continues, investors may start to doubt the company’s future prospects and this may affect its stock price adversely in the long-term. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Inmode Ltd. More…
| Total Revenues | Net Income | Net Margin |
| 496.96 | 182.73 | 36.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Inmode Ltd. More…
| Operations | Investing | Financing |
| 176.86 | -108.96 | 3.69 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Inmode Ltd. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 734.08 | 67.93 | 6.66 |
Key Ratios Snapshot
Some of the financial key ratios for Inmode Ltd are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 46.4% | 63.9% | 42.6% |
| FCF Margin | ROE | ROA |
| 35.3% | 23.9% | 18.0% |
Analysis – Inmode Ltd Intrinsic Value Calculator
At GoodWhale, we have done a thorough financial analysis of INMODE LTD, and have found that the fair value of their share is around $52.5. This valuation is based on our proprietary Valuation Line, which takes into account various factors such as current assets, liabilities, and earnings. Currently, INMODE LTD stock is traded at $44.1, meaning that it is currently undervalued by 16.0%. This presents an opportunity for investors who are looking for a good long-term investment. By investing in INMODE LTD at this price, they can benefit from the potential upside in the stock as it moves closer to its fair value. More…
Peers
The market for aesthetic medical device is highly competitive with InMode Ltd. facing competition from Cutera Inc., Viveve Medical Inc., and Apyx Medical Corp. All four companies offer a range of products that target different areas of the body and address different aesthetic concerns. InMode Ltd. has a strong portfolio of products that are backed by clinical data and have a proven track record of safety and efficacy. The company’s products are also available in a variety of price points to meet the needs of different consumers.
– Cutera Inc ($NASDAQ:CUTR)
Cutera Inc is a medical device company that provides aesthetic treatments to patients worldwide. Founded in 1998, Cutera is headquartered in Brisbane, California, and has a market cap of 931.59M as of 2022. The company’s Return on Equity is -111.73%. Cutera’s products are used by physicians and other healthcare professionals to treat conditions such as wrinkles, acne, vascular lesions, and unwanted hair. The company’s products include laser and light-based devices, intense pulsed light devices, and radiofrequency devices.
– Viveve Medical Inc ($NASDAQ:VIVE)
Viveve Medical Inc. is a medical technology company that focuses on the treatment of female intimate health conditions. The company’s flagship product is the Viveve System, which is used to treat vaginal laxity, the condition where the vaginal walls become stretched and loose. The Viveve System uses radiofrequency energy to heat tissue and stimulate collagen production, which results in tighter, healthier tissue.
Viveve Medical Inc has a market cap of 6.19M as of 2022. The company’s Return on Equity is -179.17%. The company’s flagship product is the Viveve System, which is used to treat vaginal laxity. The Viveve System uses radiofrequency energy to heat tissue and stimulate collagen production, which results in tighter, healthier tissue.
– Apyx Medical Corp ($NASDAQ:APYX)
Apyx Medical Corp is a medical device company that develops, manufactures, and markets radiofrequency (RF) products for the global surgical market. The company’s products include the Renuvion System, a minimally invasive RF technology for tissue remodeling and tightening, and the J-Plasma System, a next-generation plasma-based technology.
Apyx Medical Corp has a market cap of 149.01M as of 2022, a Return on Equity of -22.62%. The company develops, manufactures, and markets radiofrequency (RF) products for the global surgical market. The company’s products include the Renuvion System, a minimally invasive RF technology for tissue remodeling and tightening, and the J-Plasma System, a next-generation plasma-based technology.
Summary
INMODE LTD reported significantly positive financial results for the second quarter of 2023. The company saw a 19.8% year-over-year increase in total revenue to USD 136.1 million and a 26.5% increase in net income to USD 55.7 million. These strong results are likely to be encouraging to investors and may lead to further investment in the company.
INMODE’s strong performance may be due to its innovative products, increased demand for its services, or a combination of both. Investors should consider these results when deciding whether to invest in this company.
